These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11164700)

  • 21. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
    McCormack PL
    Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
    Arzimanoglou A; Ferreira JA; Satlin A; Mendes S; Williams B; Critchley D; Schuck E; Hussein Z; Kumar D; Dhadda S; Bibbiani F
    Eur J Paediatr Neurol; 2016 May; 20(3):393-402. PubMed ID: 26805435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies.
    Grosso S; Coppola G; Dontin SD; Gobbi G; Pruna D; Accorsi P; Verrotti A; Parisi P; Balestri P
    Eur J Paediatr Neurol; 2014 Sep; 18(5):641-5. PubMed ID: 24912730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of rufinamide in drug-resistant epilepsy: A meta-analysis of double-blind, randomized, placebo controlled trials.
    Xu Z; Zhao H; Chen Z
    Epilepsy Res; 2016 Feb; 120():104-10. PubMed ID: 26811934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of rufinamide in childhood refractory epilepsy.
    Yıldız EP; Hızlı Z; Bektaş G; Ulak-Özkan M; Tatlı B; Aydınlı N; Çalışkan M; Özmen M
    Turk J Pediatr; 2018; 60(3):238-243. PubMed ID: 30511535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies.
    Wheless JW; Conry J; Krauss G; Mann A; LoPresti A; Narurkar M
    J Child Neurol; 2009 Dec; 24(12):1520-5. PubMed ID: 19955344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rufinamide: a new anti-epileptic medication.
    Hakimian S; Cheng-Hakimian A; Anderson GD; Miller JW
    Expert Opin Pharmacother; 2007 Aug; 8(12):1931-40. PubMed ID: 17696794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea.
    Lee EH; Yum MS; Ko TS
    Clin Neurol Neurosurg; 2013 Jul; 115(7):926-9. PubMed ID: 23083943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
    Nikanorova M; Brandt C; Auvin S; McMurray R
    Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials.
    Alsaad AM; Koren G
    Br J Clin Pharmacol; 2014 Dec; 78(6):1264-71. PubMed ID: 25132372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rufinamide for the treatment of Lennox-Gastaut syndrome.
    Besag FM
    Expert Opin Pharmacother; 2011 Apr; 12(5):801-6. PubMed ID: 21348771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models.
    White HS; Franklin MR; Kupferberg HJ; Schmutz M; Stables JP; Wolf HH
    Epilepsia; 2008 Jul; 49(7):1213-20. PubMed ID: 18325020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience.
    Coppola G; Grosso S; Franzoni E; Veggiotti P; Zamponi N; Parisi P; Spalice A; Habetswallner F; Fels A; Capovilla G; Verrotti A; Mangano S; Balestri A; Curatolo P; Pascotto A
    Seizure; 2010 Nov; 19(9):587-91. PubMed ID: 20888268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders.
    Cusmai R; Verrotti A; Moavero R; Curatolo P; Battaglia D; Matricardi S; Spalice A; Vigevano F; Pruna D; Parisi P; D'Aniello A; Di Gennaro G; Coppola G
    Epilepsy Res; 2014 Mar; 108(3):542-6. PubMed ID: 24548548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group.
    Privitera M; Fincham R; Penry J; Reife R; Kramer L; Pledger G; Karim R
    Neurology; 1996 Jun; 46(6):1678-83. PubMed ID: 8649569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis.
    Verrotti A; Loiacono G; Ballone E; Mattei PA; Chiarelli F; Curatolo P
    Pediatr Neurol; 2011 May; 44(5):347-9. PubMed ID: 21481742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.
    Faught E; Wilder BJ; Ramsay RE; Reife RA; Kramer LD; Pledger GW; Karim RM
    Neurology; 1996 Jun; 46(6):1684-90. PubMed ID: 8649570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.